Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China

被引:0
作者
Jian, Yuan [1 ]
Zhou, Huixing [1 ]
Xie, Weiwei [2 ]
Ren, Yuan [3 ]
Zhang, Zhiyao [1 ]
Yang, Guangzhong [1 ]
Geng, Chuanying [1 ]
Jia, Jing [1 ]
Chen, Wenming [1 ]
Huang, Wenrong [3 ]
Cen, Xinan [2 ]
Gao, Wen [1 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China
[2] Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China
[3] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Hematol, Beijing, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 04期
基金
北京市自然科学基金;
关键词
Multiple myeloma; renal impairment; dialysis dependence; dialysis independence; survival; DIAGNOSIS; RECOVERY; POPULATION; MORTALITY; FAILURE; OUTCOMES; THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal impairment (RI) is a very common complication of multiple myeloma (MM) with a negative impact on survival. Herein we retrospectively analyzed 334 MM patients with renal impairment at diagnosis from three hospi-tals in China. All 334 patients were divided into three groups, including dialysis dependence (n=43), dialysis inde-pendence (n=42), and without dialysis (n=249). Compared with dialysis independence and without dialysis groups, dialysis dependence group had the lowest overall hematologic response (48.8% vs. 97.6% vs. 77.1%, P<0.001) and overall renal response (0.0% vs. 97.6% vs. 72.7%, P<0.001), as well as the highest early mortality within 24 months (50.0% vs. 24.4% vs. 26.3%, P=0.006). Dialysis dependence group had similar progression-free survival (24 vs. 26 vs. 27 months, P=0.231) and significantly shorter overall survival (25 vs. 69 vs. 45 months, P=0.001). Dialysis dependence was independently associated with high mortality within 24 months and shorter overall survival. In conclusion, MM patients with dialysis dependence still tend to suffer a dismal disease course, including a high probability to suffer early mortality, worse hematological and renal response, as well as shorter survival. Dialysis independence could be very promising for survival improvement.
引用
收藏
页码:1571 / 1581
页数:11
相关论文
共 50 条
  • [41] Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China
    Hailu Sun
    Aijun Liu
    Lihong Liu
    Wei Wang
    Zhen Cai
    Hua Yan
    Lijuan Chen
    Guangxun Gao
    Fang Wang
    Aijun Liao
    Bing Chen
    Jia Feng
    Juan Li
    Dong-Ping Huang
    Da Gao
    Qi-Ke Zhang
    Jun Luo
    Rong Fu
    Juan Du
    Jin Lu
    [J]. BMC Cancer, 23
  • [42] Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China
    Sun, Hailu
    Liu, Aijun
    Liu, Lihong
    Wang, Wei
    Cai, Zhen
    Yan, Hua
    Chen, Lijuan
    Gao, Guangxun
    Wang, Fang
    Liao, Aijun
    Chen, Bing
    Feng, Jia
    Li, Juan
    Huang, Dong-Ping
    Gao, Da
    Zhang, Qi-Ke
    Luo, Jun
    Fu, Rong
    Du, Juan
    Lu, Jin
    [J]. BMC CANCER, 2023, 23 (01)
  • [43] Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study
    Marlies Antlanger
    Tobias Dust
    Thomas Reiter
    Alexandra Böhm
    Wolfgang W. Lamm
    Max Gornicec
    Ella Willenbacher
    David Nachbaur
    Roman Weger
    Werner Rabitsch
    Susanne Rasoul-Rockenschaub
    Nina Worel
    Daniel Lechner
    Hildegard Greinix
    Felix Keil
    Heinz Gisslinger
    Hermine Agis
    Maria-Theresa Krauth
    [J]. BMC Cancer, 18
  • [44] Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience
    Nesr, George
    Shah, Raakhee
    Kyriakou, Charalampia
    Sive, Jonathan
    Popat, Rakesh
    Yong, Kwee
    Wisniowski, Brendan
    Xu, Ke
    Wechalekar, Ashu
    Lee, Lydia
    Ings, Stuart
    Papanikolaou, Xenofon
    Mahmood, Shameem
    Mcmillan, Annabel
    Horder, Jackie
    Newrick, Fiona
    Marfil, Jotham
    Ainley, Louise
    Asher, Samir
    Cheesman, Simon
    Rabin, Neil
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1465 - 1471
  • [45] Autologous stem cell transplantation in multiple myeloma patients with renal impairment
    Zhai, Yingying
    Yan, Lingzhi
    Jin, Song
    Yan, Shuang
    Yao, Weiqin
    Shang, Jingjing
    Shi, Xiaolan
    Wang, Ruju
    Kang, Huizhu
    Lu, Jing
    Zhu, Ziling
    Tang, Fang
    Wei, Feng
    Fu, Chengcheng
    Wu, Depei
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (03) : 621 - 628
  • [46] Autologous stem cell transplantation in multiple myeloma patients with renal impairment
    Yingying Zhai
    Lingzhi Yan
    Song Jin
    Shuang Yan
    Weiqin Yao
    Jingjing Shang
    Xiaolan Shi
    Ruju Wang
    Huizhu Kang
    Jing Lu
    Ziling Zhu
    Fang Tang
    Feng Wei
    Chengcheng Fu
    Depei Wu
    [J]. Annals of Hematology, 2023, 102 : 621 - 628
  • [47] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    Kumar, S. K.
    Lee, J. H.
    Lahuerta, J. J.
    Morgan, G.
    Richardson, P. G.
    Crowley, J.
    Haessler, J.
    Feather, J.
    Hoering, A.
    Moreau, P.
    LeLeu, X.
    Hulin, C.
    Klein, S. K.
    Sonneveld, P.
    Siegel, D.
    Blade, J.
    Goldschmidt, H.
    Jagannath, S.
    Miguel, J. S.
    Orlowski, R.
    Palumbo, A.
    Sezer, O.
    Rajkumar, S. V.
    Durie, B. G. M.
    [J]. LEUKEMIA, 2012, 26 (01) : 149 - 157
  • [48] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    S K Kumar
    J H Lee
    J J Lahuerta
    G Morgan
    P G Richardson
    J Crowley
    J Haessler
    J Feather
    A Hoering
    P Moreau
    X LeLeu
    C Hulin
    S K Klein
    P Sonneveld
    D Siegel
    J Bladé
    H Goldschmidt
    S Jagannath
    J S Miguel
    R Orlowski
    A Palumbo
    O Sezer
    S V Rajkumar
    B G M Durie
    [J]. Leukemia, 2012, 26 : 149 - 157
  • [49] A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?
    Piro, Eugenio
    Molica, Stefano
    [J]. ACTA HAEMATOLOGICA, 2011, 126 (03) : 163 - 168
  • [50] Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment
    Joao, Cristina
    Freitas, Jose
    Gomes, Fernando
    Geraldes, Catarina
    Coelho, Ines
    Neves, Manuel
    Lucio, Paulo
    Esteves, Susana
    Esteves, Graca V.
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (06) : 931 - 936